+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Drug Screening Market Overview, 2023-2028

  • PDF Icon

    Report

  • 85 Pages
  • November 2023
  • Region: Global
  • Bonafide Research
  • ID: 5918095
10% Free customization
1h Free Analyst Time
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In an era marked by fast-paced lifestyles, evolving societal norms, and increasing concerns over substance abuse, the Drug Testing industry stands as a crucial pillar supporting safety, compliance, and public health. The need for rigorous and standardized drug testing has become more pronounced than ever, spanning various sectors such as the workplace, sports, and healthcare. The workplace is a microcosm of diverse individuals contributing to the smooth functioning of organizations. Ensuring the safety of employees and maintaining productivity are paramount concerns for employers. Drug testing programs play a pivotal role in identifying and addressing substance abuse issues that may compromise workplace safety. Industries with safety-sensitive positions, such as transportation and manufacturing, heavily rely on drug testing to prevent accidents and promote a secure working environment.

Governments and regulatory bodies around the world have recognized the importance of drug testing in various sectors. Workplace regulations mandate drug testing in specific industries to ensure compliance with safety standards. These regulations not only protect employees from potential harm but also safeguard employers from legal liabilities associated with substance-related incidents. In the realm of sports, maintaining integrity and fair competition is fundamental. Athletes are subject to rigorous anti-doping measures to prevent the use of performance-enhancing substances. Drug testing is not merely a regulatory requirement but a fundamental element in upholding the principles of fair play and ensuring that the outcomes of sporting events are determined by skill, training, and dedication.

According to the research report, “Global Drug Screening Market Overview, 2023-28”, the Global Drug Screening market is anticipated to cross USD 15 Billion by 2028, increasing from USD 8.95 Billion in 2022. The market is expected to grow with more than 10% CAGR by 2023-28. Within the healthcare sector, drug testing serves critical diagnostic and therapeutic functions. Physicians and healthcare professionals rely on drug tests to monitor patient adherence to prescribed medications, adjust treatment plans, and ensure optimal patient outcomes. It is an indispensable tool in managing chronic conditions and guiding medical decisions. The Drug Testing industry contributes significantly to raising awareness about substance abuse issues. By providing accurate and timely results, it helps individuals confront and overcome addiction.

Educational institutions, communities, and employers alike utilize drug testing as part of broader initiatives to promote substance abuse prevention and rehabilitation. The landscape of drug testing has evolved with technological advancements. Innovative testing methods, such as hair testing, saliva testing, and point-of-care testing, offers enhanced accuracy and convenience. These technologies contribute to making drug testing more accessible and adaptable to diverse settings, from workplaces to remote locations. While drug testing is essential, it must be conducted with due respect for individual privacy rights. Striking a balance between the need for testing and protecting the privacy of individuals is a challenge for the industry. Ethical considerations and adherence to standards are paramount in ensuring the responsible and effective implementation of drug testing programs.

Traditional urine testing methods have been supplemented and, in some cases, replaced by more advanced technologies such as hair testing, saliva testing, and sweat patch testing. These methods offer advantages in terms of detection windows, ease of collection, and accuracy. The industry has witnessed a growing trend towards POCT, allowing for on-site testing with rapid results. This is particularly beneficial for industries requiring immediate decisions, such as law enforcement and healthcare. Over time, the scope of drug testing panels has expanded to include a broader range of substances. Initially focused on common drugs like marijuana, cocaine, and opiates, testing panels now often include synthetic drugs and prescription medications. Regulatory frameworks governing drug testing have evolved to adapt to societal needs and advances in testing methodologies. Changes in workplace regulations, especially in safety-sensitive industries, have driven the adoption of drug testing programs.

Companies have increasingly recognized the importance of maintaining a drug-free workplace. Drug testing is now a standard practice in many industries, and companies often incorporate testing into their overall occupational health and safety programs. The COVID-19 pandemic has accelerated the adoption of remote and mobile testing services. Individuals can now conduct tests at home or at remote locations, with samples collected and analyzed through convenient and secure methods. The integration of AI and data analytics has become a trend in the drug testing industry. These technologies enhance the interpretation of results, improve efficiency, and assist in managing large datasets. As awareness of privacy concerns has grown, the industry has had to adapt to ensure that testing procedures comply with legal standards.

This includes addressing issues related to employee consent, confidentiality, and protection of individual rights. Drug testing is no longer limited to the workplace; it has expanded into areas such as sports, education, and healthcare. Athletes, students, and healthcare professionals may undergo drug testing as part of regulatory requirements or professional standards.

The Asia-Pacific region has emerged as a rapidly growing hub in the Drug Testing industry market due to a confluence of factors driving demand for robust testing solutions. The region's expanding economies, industrialization, and a rising awareness of the importance of workplace safety and public health are key contributors. Stringent regulatory measures imposed by governments to ensure a drug-free workplace and comply with international standards have spurred the adoption of drug testing programs across various industries. Additionally, the increasing prevalence of substance abuse issues and the associated societal concerns have fueled the demand for comprehensive testing services. The region's dynamic technological landscape has facilitated the integration of advanced testing methodologies, including point-of-care testing and innovative sample collection methods.

As Asia-Pacific continues to undergo rapid urbanization and industrial growth, the Drug Testing industry is well-positioned to thrive, addressing the evolving needs of workplaces, sports organizations, and healthcare institutions in the region. The industry's growth in Asia-Pacific reflects a commitment to creating safer and healthier environments, aligning with global trends in promoting well-being and ensuring compliance with regulatory standards. The rapid growth of Rapid Testing Devices in the Drug Testing industry market can be attributed to several key factors that address the evolving needs of stakeholders across various sectors.

One of the primary drivers is the demand for quick and on-the-spot results, especially in scenarios where immediate decisions are critical. Rapid Testing Devices offer unparalleled advantages in terms of speed, providing results in minutes rather than hours or days, thus enhancing efficiency and productivity in diverse settings.

In industries such as transportation, law enforcement, and healthcare, where time-sensitive decisions are crucial, these devices play a pivotal role. Additionally, the convenience and ease of use associated with rapid testing contribute to their widespread adoption. The technology's ability to detect a broad range of substances while ensuring accuracy has further fueled its popularity. In the context of the COVID-19 pandemic, the accelerated adoption of rapid testing for infectious diseases has also heightened awareness and acceptance of rapid testing devices in general. As the emphasis on quick and reliable results continues to grow, the Drug Testing industry is witnessing an upward trajectory for Rapid Testing Devices, making them an indispensable component in the contemporary landscape of drug testing methodologies.

Oral fluid samples have witnessed a substantial surge in popularity within the Drug Testing industry market due to several compelling reasons. The non-invasive nature of oral fluid collection, accomplished through saliva samples, offers a distinct advantage over traditional methods such as urine or blood testing. This ease of collection translates into increased convenience for both individuals undergoing testing and those administering it. Furthermore, oral fluid samples provide a shorter detection window compared to urine, making them particularly useful for detecting recent drug use. The growing recognition of the correlation between oral fluid testing and impairment levels has also fueled its adoption, especially in safety-sensitive industries where real-time assessments of cognitive functions are crucial.

As regulatory frameworks evolve to accommodate innovative testing methods, the versatility, and accuracy of oral fluid testing contribute to its expanding presence in workplace testing, roadside screening, and other applications. The rising emphasis on efficient and user-friendly drug testing solutions positions oral fluid samples as a significant driver in the continuous growth of the Drug Testing industry. The growth of hospitals in the Drug Testing industry market is a testament to the expanding role of healthcare institutions in addressing comprehensive patient care, safety, and treatment monitoring.

Hospitals have increasingly integrated drug testing into their diagnostic protocols, not only for emergency situations but also for routine medical care. The need to identify and manage substance abuse issues among patients has become a critical aspect of healthcare, influencing treatment plans and ensuring optimal patient outcomes.

Drug testing in hospitals aids physicians in making informed decisions regarding medication management, pain management, and the overall well-being of patients. Additionally, as part of pre-surgical assessments and in managing chronic conditions, drug testing has become standard practice, contributing to a more holistic approach to healthcare. The emphasis on patient safety and the rising awareness of the impact of substance abuse on health outcomes have positioned hospitals at the forefront of the Drug Testing industry, reflecting a commitment to delivering high-quality, comprehensive healthcare services.

Companies Covered in this report:

Abbott Laboratories, Laboratory Corporation, Drägerwerk AG & Co. KGaA, Siemens Healthineers, Shimadzu Corporation, OraSure Technologies, Quest Diagnostics, Lifeloc Technologies, Inc, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Psychemedics Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc.

Market Drivers

  • Occupational Health and Safety Concerns: The increasing focus on occupational health and safety, especially in high-risk industries such as construction and mining, is driving the demand for drug testing. Ensuring a drug-free workplace is crucial for preventing accidents and ensuring employee well-being.
  • Rise in Drug Abuse among the Youth: The prevalence of drug abuse among the youth population has led to an increased emphasis on drug testing in schools, colleges, and universities. Educational institutions are implementing testing programs to address this growing concern.

Market Challenges

  • Cost Constraints and Affordability: The costs associated with implementing and maintaining drug testing programs can be a challenge for some organizations, particularly smaller businesses. Striking a balance between effective testing and cost management remains a concern.
  • Detection of Synthetic and Designer Drugs: The continuous development and use of synthetic and designer drugs pose a challenge for traditional drug testing methods. Staying ahead of emerging substances and adapting testing protocols to detect these newer compounds is an ongoing challenge.

Market Trends

  • Expanding Application in Sports and Entertainment: Drug testing is increasingly being applied in sports and the entertainment industry to ensure fair competition and meet regulatory requirements. Athletes and performers are subject to regular testing to detect performance-enhancing substances and illicit drugs.
  • Remote and Mobile Testing Services: The COVID-19 pandemic has accelerated the adoption of remote and mobile testing services. This trend involves individuals being tested at home or at remote locations, with samples collected and analyzed through convenient and secure methods.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the global drug testing market, introducing both challenges and opportunities. The widespread disruptions in supply chains, limitations on workforce mobility, and economic uncertainties have posed challenges to the implementation of drug testing programs. Many businesses faced operational constraints, leading to a temporary slowdown in routine testing activities. However, the pandemic has also underscored the importance of maintaining a drug-free workplace, especially in essential industries such as healthcare and transportation. Additionally, the adoption of remote and mobile testing services has gained traction as a response to the need for decentralized testing during lockdowns and social distancing measures.

The heightened awareness of health and safety issues has reinforced the demand for drug testing solutions, particularly in sectors critical to pandemic response efforts. As the world adapts to the evolving dynamics of the post-pandemic era, the drug testing market is likely to witness continued innovation, with an emphasis on flexible and accessible testing solutions that address both workplace and public health needs.

Key Developments

  • In December 2022, PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).
  • In April 2022, Saladax Biomedical, Inc acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries.
  • In April 2022, Janssen Pharmaceutical NV sold its patent portfolio for antipsychotic medication testing to Saladax Biomedical, Inc. There are seventeen patent families in this intellectual property (IP) portfolio. The company now holds a leading position in the antipsychotic drug testing industry because of this strategy.

Considered in this report:

  • Geography: Global
  • Historic year: 2017
  • Base year: 2022
  • Estimated year: 2023
  • Forecast year: 2028

Aspects covered in this report:

  • Global Drug Screening market with its value and forecast along with its segments
  • Region-wise Drug Screening market analysis
  • Various drivers and challenges
  • On-going trends and developments
  • Top profiled companies
  • Strategic recommendation

Regions covered in the report

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle-East & Africa

By Product and Service

  • Consumables
  • Analytical Instruments
  • Rapid Testing Devices
  • Drug Screening Service

By Sample Type

  • Urine Samples
  • Breath Samples
  • Hair Samples
  • Oral Fluid Samples
  • Other Samples

By End User

  • Laboratories
  • Workplaces
  • Hospitals
  • Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drug Screening industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.


This product will be delivered within 2 business days.

Table of Contents

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. COVID-19 Effect
2.5. Supply chain Analysis
2.6. Policy & Regulatory Framework
2.7. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Drug Screening Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Product and Service
6.5. Market Size and Forecast, By Sample Type
6.6. Market Size and Forecast, By End User
7. North America Drug Screening Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Product and Service
7.4. Market Size and Forecast, By Sample Type
7.5. Market Size and Forecast, By End User
8. Europe Drug Screening Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Product and Service
8.4. Market Size and Forecast, By Sample Type
8.5. Market Size and Forecast, By End User
9. Asia-Pacific Drug Screening Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Product and Service
9.4. Market Size and Forecast, By Sample Type
9.5. Market Size and Forecast, By End User
10. South America Drug Screening Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Product and Service
10.4. Market Size and Forecast, By Sample Type
10.5. Market Size and Forecast, By End User
11. Middle East & Africa Drug Screening Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Product and Service
11.4. Market Size and Forecast, By Sample Type
11.5. Market Size and Forecast, By End User
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2022
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Abbott Laboratories
12.6.1.1. Company Snapshot
12.6.1.2. Company Overview
12.6.1.3. Financial Highlights
12.6.1.4. Geographic Insights
12.6.1.5. Business Segment & Performance
12.6.1.6. Product Portfolio
12.6.1.7. Key Executives
12.6.1.8. Strategic Moves & Developments
12.6.2. Laboratory Corporation
12.6.3. Drägerwerk AG & Co. KGaA
12.6.4. Siemens Healthineers
12.6.5. Shimadzu Corporation
12.6.6. OraSure Technologies
12.6.7. Quest Diagnostics
12.6.8. Lifeloc Technologies, Inc
12.6.9. F. Hoffmann-La Roche AG
12.6.10. Bio-Rad Laboratories, Inc.
13. Strategic Recommendations
14. Annexure
14.1. FAQs
14.2. Notes
14.3. Related Reports
15. Disclaimer
List of Figures
Figure 1: Global Drug Screening Market Size (USD Billion) By Region, 2022 & 2028
Figure 2: Market attractiveness Index, By Region 2028
Figure 3: Market attractiveness Index, By Segment 2028
Figure 4: Global Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 5: Global Drug Screening Market Share By Region (2022)
Figure 6: North America Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 7: North America Drug Screening Market Share By Country (2022)
Figure 8: Europe Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 9: Europe Drug Screening Market Share By Country (2022)
Figure 10: Asia-Pacific Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 11: Asia-Pacific Drug Screening Market Share By Country (2022)
Figure 12: South America Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 13: South America Drug Screening Market Share By Country (2022)
Figure 14: Middle East & Africa Drug Screening Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 15: Middle East & Africa Drug Screening Market Share By Country (2022)
Figure 16: Competitive Dashboard of top 5 players, 2022
Figure 17: Market Share insights of key players, 2022
Figure 18: Porter's Five Forces of Global Drug Screening Market
List of Tables
Table 1: Global Drug Screening Market Snapshot, By Segmentation (2022 & 2028) (in USD Billion)
Table 2: Influencing Factors for Drug Screening Market, 2022
Table 3: Top 10 Counties Economic Snapshot 2020
Table 4: Economic Snapshot of Other Prominent Countries 2020
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Drug Screening Market Size and Forecast, By Geography (2017 to 2028F) (In USD Billion)
Table 7: Global Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 8: Global Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 9: Global Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)
Table 10: North America Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 11: North America Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 12: North America Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)
Table 13: Europe Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 14: Europe Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 15: Europe Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)
Table 16: Asia-Pacific Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 17: Asia-Pacific Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 18: Asia-Pacific Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)
Table 19: South America Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 20: South America Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 21: South America Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)
Table 22: Middle East & Africa Drug Screening Market Size and Forecast, By Product and Service (2017 to 2028F) (In USD Billion)
Table 23: Middle East & Africa Drug Screening Market Size and Forecast, By Sample Type (2017 to 2028F) (In USD Billion)
Table 24: Middle East & Africa Drug Screening Market Size and Forecast, By End User (2017 to 2028F) (In USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Laboratory Corporation
  • Drägerwerk AG & Co. KGaA
  • Siemens Healthineers
  • Shimadzu Corporation
  • OraSure Technologies
  • Quest Diagnostics
  • Lifeloc Technologies, Inc
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories, Inc.